Media Articles Related to Zarontin (Ethosuximide)
Primary data from Phase 3 study evaluating brivaracetam as adjunctive treatment of partial-onset seizures in epilepsy announced
Source: Clinical Trials / Drug Trials News From Medical News Today [2014.12.11]
UCB has announced the primary efficacy and safety data from the latest Phase 3 study evaluating brivaracetam (fixed doses of 100 and 200 mg/day with no up-titration) as adjunctive treatment in...
UCG and Emory present new assessment of epilepsy prevalence and incidence in the U.S.
Source: Epilepsy News From Medical News Today [2014.12.10]
The Department of Neurology at Emory University School of Medicine and UCB, a global biopharmaceutical company with a focus on epilepsy treatment and research, have announced results of the first...
Positive Results With Brivaracetam, Perampanel, in Epilepsy
Source: Medscape NeurologyHeadlines [2014.12.08]
Researchers are reporting positive phase 3 trials of two antiepileptic drugs, one of which
Medscape Medical News
Benefits Pile Up for Epilepsy Surgery
Source: MedPage Today Pediatrics [2014.12.08]
(MedPage Today) -- When surgery is an option, studies suggest it's usually the best one.
Pain Complaints, Opioid Use Higher With Epilepsy
Source: MedPage Today Psychiatry [2014.12.07]
(MedPage Today) -- Findings may reflect comorbidities linked to seizure disorders.
Published Studies Related to Zarontin (Ethosuximide)
Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. [2010.03.04]
BACKGROUND: Childhood absence epilepsy, the most common pediatric epilepsy syndrome, is usually treated with ethosuximide, valproic acid, or lamotrigine. The most efficacious and tolerable initial empirical treatment has not been defined... CONCLUSIONS: Ethosuximide and valproic acid are more effective than lamotrigine in the treatment of childhood absence epilepsy. Ethosuximide is associated with fewer adverse attentional effects. (ClinicalTrials.gov number, NCT00088452.) 2010 Massachusetts Medical Society
Effect of intracranial administration of ethosuximide in rats with spontaneous or pentylenetetrazol-induced spike-wave discharges. [2011.07]
PURPOSE: Generalized absence seizures are characterized by bilateral spike-wave discharges (SWDs), particularly in the frontoparietal cortical region. In WAG/Rij and GAERS rats with absence epilepsy, recent evidence indicates that SWDs arise first from the lateral somatosensory cortex (LSC), that is, the cortical focus theory...
Comparison of the antiepileptogenic effects of an early long-term treatment with ethosuximide or levetiracetam in a genetic animal model of absence epilepsy. [2010.08]
PURPOSE: Epilepsy is a heterogeneous syndrome characterized by recurrent, spontaneous seizures; continuous medication is, therefore, necessary, even after the seizures have long been suppressed with antiepileptic drug (AED) treatments. The most disturbing issue is the inability of AEDs to provide a persistent cure, because these compounds generally suppress the occurrence of epileptic seizures without necessarily having antiepileptogenic properties...
Ethosuximide converts ictogenic neurons initiating absence seizures into normal neurons in a genetic model. [2009.07]
Absence epilepsy is a form of generalized epilepsy commonly seen in children. The neuronal process by which ethosuximide (ETX), a first choice anti-absence drug, prevents absence seizures is still unresolved...
Interactions of tiagabine with ethosuximide in the mouse pentylenetetrazole-induced seizure model: an isobolographic analysis for non-parallel dose-response relationship curves. [2008.11]
The aim of this study was to characterize the interaction between tiagabine (TGB) and ethosuximide (ETS), two antiepileptic drugs, in pentylenetetrazole (PTZ)-induced clonic seizures in mice using isobolographic analysis. The nature of the interaction between the drugs administered in combination was ascertained by estimating plasma and brain concentrations of ETS and TGB using fluorescence polarization immunoassay (FPIA) and high-performance liquid chromatography (HPLC)...
Clinical Trials Related to Zarontin (Ethosuximide)
Safety and Efficacy Study of Ethosuximide for the Treatment of Complex Regional Pain Syndrome (CRPS). [Recruiting]
Pain remains the most debilitating symptom for adult patients suffering from complex
regional pain syndrome (CRPS). Most CRPS patients gain little to no relief from current
painkillers. The purpose of this study is to evaluate the efficacy and safety of
ethosuximide in search of much-needed adjunctive therapy to relieve the pain and suffering
associated with CRPS.
Chemotherapy Induced Painful Peripheral Neuropathy Ethosuximide (The CIN-E Study) [Recruiting]
This study is a drug trial of ethosuximide as a painkiller if you develop pain as a side
effect of chemotherapy. Ethosuximide will be compared against placebo (an inactive
substance) to test whether any response is a true effect of the drug, and not a 'placebo
Comparison of a Drug and Placebo in the Prevention of Migraine Headaches [Not yet recruiting]
The purpose of this study is to determine whether ethosuximide works better than placebo in
the prevention of episodic migraine among veterans.
Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study [Active, not recruiting]
Ketogenic Diet vs.Antiepileptic Drug Treatment in Drug Resistant Epilepsy [Recruiting]
This is an open randomized controlled study in children with mental retardation and
refractory epilepsy in which treatment with ketogenic diet (KD) is compared with treatment
with the antiepileptic drug (AED), not tried by the patient before, which we consider to be
the most appropriate AED for the patient.
Reports of Suspected Zarontin (Ethosuximide) Side Effects
Drug Ineffective (3),
Poor Quality Drug Administered (3),
Mycoplasma Infection (2),
Abdominal Discomfort (2),
Stevens-Johnson Syndrome (2),
Oral Infection (2),
Toxic Epidermal Necrolysis (2), more >>